Roche Receives FDA De Novo Authorization for Mass Spectrometry Platform
The FDA authorized Roche’s cobas pro i 601 platform with the Ionify Gabapentin assay for its cobas Mass Spec solution.
The FDA authorized Roche’s cobas pro i 601 platform with the Ionify Gabapentin assay for its cobas Mass Spec solution.